RenovoRx, Inc. (RNXT)
1.33
-0.16
(-10.74%)
USD |
NASDAQ |
Oct 30, 16:00
1.34
+0.01
(+0.75%)
After-Hours: 20:00
RenovoRx Price to Book Value : 6.684 for Oct. 30, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 6.684 |
| October 29, 2026 | 7.488 |
| October 28, 2026 | 7.161 |
| October 27, 2026 | 6.985 |
| October 26, 2026 | 6.583 |
| October 23, 2026 | 6.483 |
| October 22, 2026 | 6.382 |
| October 21, 2026 | 6.181 |
| October 20, 2026 | 6.030 |
| October 19, 2026 | 5.830 |
| October 16, 2026 | 5.729 |
| October 15, 2026 | 5.980 |
| October 14, 2026 | 5.628 |
| October 13, 2026 | 5.779 |
| October 12, 2026 | 6.282 |
| October 09, 2026 | 6.432 |
| October 08, 2026 | 6.684 |
| October 07, 2026 | 6.885 |
| October 06, 2026 | 6.985 |
| October 05, 2026 | 7.387 |
| October 02, 2026 | 7.940 |
| October 01, 2026 | 7.789 |
| September 30, 2026 | 7.840 |
| September 29, 2026 | 7.890 |
| September 28, 2026 | 7.789 |
| Date | Value |
|---|---|
| September 25, 2026 | 8.342 |
| September 24, 2026 | 8.443 |
| September 23, 2026 | 8.191 |
| September 22, 2026 | 8.543 |
| September 21, 2026 | 8.392 |
| September 18, 2026 | 8.493 |
| September 17, 2026 | 8.694 |
| September 16, 2026 | 7.789 |
| September 15, 2026 | 8.644 |
| September 14, 2026 | 8.493 |
| September 11, 2026 | 8.845 |
| September 10, 2026 | 8.895 |
| September 09, 2026 | 10.03 |
| September 08, 2026 | 11.06 |
| September 04, 2026 | 12.01 |
| September 03, 2026 | 11.91 |
| September 02, 2026 | 12.66 |
| September 01, 2026 | 10.60 |
| August 31, 2026 | 9.699 |
| August 28, 2026 | 8.392 |
| August 27, 2026 | 7.438 |
| August 26, 2026 | 7.488 |
| August 25, 2026 | 7.136 |
| August 24, 2026 | 6.282 |
| August 21, 2026 | 6.634 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 3.086 |
| Travere Therapeutics, Inc. | 193.52 |
| REGENXBIO, Inc. | 5.434 |
| Krystal Biotech, Inc. | 7.236 |
| ACADIA Pharmaceuticals, Inc. | 2.712 |
Price to Book Value Related Metrics
| PS Ratio | 26.69 |
| Price | 1.33 |
| Earnings Yield | -23.61% |
| Market Cap | 60.01M |